When Kailera Therapeutics priced its IPO at $16 per share on Thursday evening, it was already doing something that hadn’t happened in the biotech sector in five years: raising $625 million in a single public market debut. When trading opened Friday morning on the Nasdaq Global Select Market, the stock climbed straight to $26 and […]
Boston’s biotech scene may be gearing up for another high-profile IPO moment—this time led by a company betting big on the future of depression treatment. Seaport Therapeutics, a relatively young but well-funded player based in the city’s Seaport district, is preparing to enter public markets with a clear mission: push its pipeline of neuropsychiatric drugs
Most cancer drugs that kill tumors also damage healthy tissue. That is not a flaw in the design — it is the fundamental problem that oncology has been trying to solve for decades. And it is the problem that Stipple Bio, a Cambridge-based biotechnology company that emerged from stealth this week with a heavily oversubscribed
Cambridge-based Biogen announced it will acquire Apellis Pharmaceuticals, headquartered in Waltham, in an all-cash deal worth approximately $5.6 billion — or $41 per share. When Apellis stock closed on Monday, it was trading at roughly half that. By Tuesday morning, shares had more than doubled overnight. That kind of move tells you something about what
Fifty million dollars is a serious amount of money for a company that started as a vaccine project in Harvard’s Innovation Lab. But then again, Ozempic is a serious amount of market — and Terrestrial Bio, the Boston-based company that just closed a $50 million Series C round, is betting it has figured out something
While most of Wall Street was still digesting the weekend business news, Vertex Pharmaceuticals dropped a clinical data release that sent its stock jumping more than 6% in premarket trading. The reason: povetacicept, the company’s experimental drug for a serious and poorly treated kidney disease, just hit its primary endpoint in a Phase 3 trial
Boston-Based Vertex Pharmaceuticals Just Delivered a Kidney Disease Breakthrough Read More »
There is a moment in 2009 that, in hindsight, changed the trajectory of modern medicine. Derrick Rossi, a stem cell biologist at Harvard Medical School, was working late in his lab on a problem that had fascinated — and frustrated — scientists for decades: how to reprogram adult human cells to behave like embryonic stem
The Untold Story of Moderna: From a Harvard Lab to the Arms of Billions Read More »
The FDA doesn’t always say no with a single word — sometimes it sends a letter. But for Watertown-based Disc Medicine, the Complete Response Letter it received this month for its lead drug bitopertin had the same effect: a hard stop that forced the company to rethink its near-term future, and to part ways with
Disc Medicine Cuts One in Five Jobs After FDA Rejects Bitopertin Application Read More »
There is a stretch of Cambridge, Massachusetts — barely a square mile in size — that has quietly become the most consequential piece of real estate in global science. On any given morning, the Red Line deposits researchers, entrepreneurs, venture capitalists, and executives from companies like Moderna, Biogen, Google, and Takeda onto the same sidewalks.
The Kendall Square Effect: The Most Valuable Square Mile in Science Read More »
In the high-stakes world of metabolic health, the next frontier isn’t a more effective injection—it’s a pill. As of late February 2026, two Boston-based startups, Vivtex and Nimbus Therapeutics, have emerged as the vanguard in the race to disrupt the $100 billion obesity market dominated by giants like Novo Nordisk and Eli Lilly. This week’s
